Video Archives

MRI-Based Prostate Cancer Screening in an Era of MCEDs

Posted by Mark Emberton, MD, FRCS | Nov 2024

Mark Emberton, MD, FRCS, discusses advancements in prostate cancer screening, emphasizing the limitations of current methods and the potential of innovative approaches.

In this 9-minute presentation, Emberton discusses emerging technologies, such as polygenic risk scoring and advanced biomarkers, that hold promise for enriching high-risk populations. Imaging, particularly bi-parametric MRI, is presented as a leading tool.

Emerton introduces TRANSFORM, a prostate cancer screening study funded by Prostate Cancer UK and the NHS. Developed through a collaborative, multidisciplinary approach, the study incorporates randomization to minimize bias and contamination. Adaptive trial design ensures underperforming methods are replaced, and novel tests can be incorporated as they emerge. Emerton expresses optimism that this innovative approach will shape the future of prostate cancer screening, addressing equity, efficiency, and scientific rigor.

How Has the SP Robot Affected Our Approach to Radical Prostatectomy?

Posted by Jeremy Slawin, MD, MBA | Nov 2024

Jeremy Slawin, MD, MBA, highlights the impact of single-port robotic technology on radical prostatectomy, emphasizing its shift from a traditional multiport, transperitoneal approach to a renewed focus on extra-peritoneal surgery.

In this 21-minute presentation, Slawin explores the evolution of prostatectomy techniques, contrasting the older extra-peritoneal open surgeries with the recent dominance of transperitoneal, multiport robotic procedures driven by advancements in minimally invasive technology. With the advent of the single-port robotic platform, surgeons are revisiting extra-peritoneal approaches.

Dr. Slawin reviews the steps for the SP robotic procedure, pointing out benefits and differences from more traditional procedures. The single-port approach allows all instruments to be introduced through a single cannula, facilitating operations in confined spaces. Slawin shares a video of the process, helping to illustrate these steps and addressing possible questions.

Early outcomes from comparative studies indicate similar surgical margin and continence rates between single-port and multiport approaches. However, there is a trend towards reduced pain, lower opioid usage, and shorter hospital stays with single-port extra-peritoneal surgeries. The challenges include a learning curve, reduced lymph node yields, and the need for technical adjustments, particularly due to arm interdependence and limited instrument strength.

How has the SP Robot Affected Our Approach to Radical Prostatectomy?

Posted by Jeremy Slawin, MD, MBA | Nov 2024

Jeremy Slawin, MD, MBA, Assistant Professor of Urology at Baylor College of Medicine in Houston, Texas, highlights single-port robotic technology for radical prostatectomy and emphasizes extraperitoneal surgery. In this 21-minute presentation, he advocates for single-port robotic systems in extra-peritoneal radical prostatectomy, highlighting its potential to enhance patient outcomes while adhering to a familiar anatomical approach.

The Bespoke Future of Cancer Care

Posted by Leonard G. Gomella, MD, FACS | Nov 2024

Leonard G. Gomella, MD, explores the concept of “bespoke” cancer care, emphasizing its personalized, patient-centered approach. Originally a British term referring to custom-made items, “bespoke” now highlights the customization of cancer treatments through precision medicine, pharmacogenomics, AI technologies, and individualized care plans.

In this 10-minute presentation, Dr. Gomella stresses that innovations in cancer care reflect the growing trend of leveraging AI to enhance screening efficiency and reduce reliance on traditional biopsy methods. He discusses how precision medicine increasingly enables oncologists to tailor treatment plans by analyzing genetic mutations and matching patients to the most promising therapies or clinical trials. The need to balance technological advancements with affordability and patient access is a central concern.

Bespoke care offers better outcomes and underscores the importance of informed decision-making, empowering patients to actively participate in their treatment journey.

Will Xenografts Take the Tragedy Out of Transplant

Posted by Michael S. Davis, MD, MBA, MHA, FACS | Nov 2024

Michael S. Davis, MD, MBA, MHA, FACS, examines the potential of renal xenografts to alleviate the organ shortage crisis in transplantation, focusing on developments in pig-to-human kidney transplants.

In this 27-minute presentation, Dr. Davis reviews the history of transplantation, tracing advancements from early animal experiments to the refinement of immunosuppressive therapies and gene editing techniques. He highlights the tragic aspects of current transplantation, noting the limited availability of donor organs. Davis presents recent studies, including preclinical trials at the University of Alabama and NYU, that demonstrated the feasibility of pig kidney transplants in brain-dead human decedents.

With an increasing number of patients awaiting kidney transplants—projected to surpass one million by 2030—the need for innovative solutions like xenotransplantation is urgent. While pig kidneys are favored, barriers such as xeno-antigenic rejection, protein incompatibility, and potential infectious disease transmission remain significant challenges.